Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

The phase 3 ARASTEP trial will investigate Nubeqa plus androgen-deprivation therapy in certain patients with hormone-sensitive prostate cancer. Researchers are looking to enroll approximately 750 ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...

ORLANDO, Fla. (Ivanhoe Newswire) --- Prostate cancer is the second leading cause of death in men right behind heart disease. Patients with this cancer often don’t find out until the disease has ...

Combining the PARP1-selective inhibitor saruparib with an androgen receptor pathway inhibitor (ARPI) demonstrated promising efficacy and safety in patients with metastatic prostate cancer, according ...

The risk difference for the group randomized to the screening invitation compared with the control group who were not invited to undergo screening was 0.11% (95% CI 0.03-0.20) for low-grade cancer and ...

Please provide your email address to receive an email when new articles are posted on . Adding radiation therapy to standard care significantly extended radiographic PFS but not OS. Radiation therapy ...